Document is current
Any future updates will be listed below
-
Authors
Farjallah, Asma
Maranda, Bruno
Giugliani, Roberto
Auray-Blais, Christiane
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals International (IISR-2020-200005, IISR-2020-200005, IISR-2020-200005)
- License Information
-
More Information
Article History
Received: 13 December 2024
Accepted: 2 February 2025
First Online: 1 March 2025
Declarations
:
: (A) Farjallah has received a research salary for her work during this project. C. Auray-Blais has received grants from Takeda Pharmaceutical International AG, as well as honoraria for lectures given from Sanofi Genzyme, BioMarin Pharmaceuticals Inc., Protalix Biotherapeutics, Amicus Therapeutics, Avrobio, and traveling expenses from Waters Corp. for lectures given. She has received service agreements from Moderna Therapeutics, Sigilon Therapeutics, and 4D Molecular Therapeutics. R. Giugliani received investigator grant, and/or consulting fees and/or speaker honoraria from Alexion, Allievex, Alnylam, Amicus, Astellas, Azafaros, BioMarin, Chiesi, Cyclo, JCR, Novartis, Paradigm, PassageBio, Pfizer, PTC, RegenxBio, Sanofi, Takeda and Ultragenyx. (B) Maranda is the medical director at MendeliKABS Inc.
